Objectives: Smokers on chronic opioid therapy (COT) for noncancer pain use prescription opioids at higher dosages and are at increased risk for opioid misuse and dependence relative to nonsmokers. The current study aims to assess whether smoking is associated with problems and concerns with COT from the perspective of the patient.
C ooccurrence of cigarette smoking and chronic pain is a critical public health concern. 1, 2 Smoking is associated with increased risk of developing chronic pain, [3] [4] [5] [6] [7] and there is a dose-response relationship between the number of cigarettes smoked per day and the likelihood of experiencing certain types of chronic pain. 1 Smokers report a greater number of painful physical sites, greater pain intensity, 8 and more functional impairment and long-term disability relative to nonsmokers. 4 Further, greater nicotine dependence is associated with more severe pain symptoms. 9 Conversely, chronic pain contributes to smoking maintenance and nicotine dependence. 1 Individuals with chronic pain often smoke cigarettes to provide a distraction, alleviate physical discomfort, 1, 10, 11 and cope with pain-related anxiety. 12 Nicotine may have short-term analgesic effects, reducing sensitivity to pain and awareness of certain painful stimuli (eg, through the activation of nicotinic acetylcholine receptors, hypothalamic-pituitaryadrenocortical activity, and the release of norepinephrine and serotonin). 1, 4 Similarly, smoking after nicotine deprivation increases tolerance for pain, whereas nicotine withdrawal is associated with increased pain sensitivity. 4 Despite the potential short-term pain inhibitory effects of nicotine, chronic exposure to tobacco smoke may sensitize pain receptors and increase pain sensitivity over time. 1 Paradoxically, smokers use significantly more analgesic medications and require higher doses relative to nonsmokers, 1 and they are more likely than nonsmokers to be on long-term opioid therapy for chronic pain. 13 Further, smoking status may be an indicator of risk for problems with prescription opioids, including aberrant prescription opioid use (eg, forging prescriptions and doctor shopping) 14 and development of opioid dependence among chronic pain patients. 15 Although a number of studies have focused on smokers with chronic pain, 1, 4 many are limited to methadone patients, and understanding of elevated risk for opioid misuse among smokers prescribed opioids for chronic noncancer pain is limited. First, to our knowledge, no studies have examined whether smoking status is associated with patients' perceived difficulties with chronic opioid therapy (COT). Understanding smokers' personal experiences with prescription opioids may illuminate psychosocial difficulties important to patients (eg, reduced activity levels and changes in mood and cognition) that differ from their clinicians' perceptions (eg, abuse and misuse). 16 Second, few studies have adjusted for behavioral health conditions associated with smoking and pain or distinguished former and never smokers. 1 Because smoking may cause changes in the central nervous system that can persist after a person has quit smoking, 4 and former smokers may differ behaviorally from nonsmokers, differentiating never and former smokers when examining smoking, pain, and opioid use is important. Finally, despite evidence that female chronic pain patients are prescribed opioids more frequently, [17] [18] [19] [20] [21] have lower levels of opioid analgesia, 4,22 utilize a lower quantity of opioids, 7 and are at decreased risk for opioid misuse and overdose 23 relative to males, few studies have examined sex-specific associations between smoking status and opioid-related outcomes among chronic pain patients.
Given the current opioid epidemic and overdose deaths, 24, 25 identifying factors pertinent to patients' perceived problems and concerns with prescription opioid use is critical. The current study examines sex-specific associations between smoking status and patient-reported problems and concerns with COT among patients prescribed opioids for noncancer chronic pain, adjusting for key covariates. We hypothesized that smokers would report a greater number of perceived problems and concerns with COT, and that the association between smoking status and perceived problems and concerns with chronic opioid therapy would vary by sex.
MATERIALS AND METHODS

Setting
We used data from the National Institute on Drug Abuse-funded Consortium to Study Opioid Risks and Trends study (CONSORT), which was developed to study long-term use of opioids for noncancer pain among adults in 2 integrated health care systems: Group Health Cooperative in Washington State and Kaiser Permanente of Northern California (KPNC). 26 The current study is limited to KPNC patients, for whom there was more detailed information on smoking behaviors. KPNC is an integrated health care delivery system that provides comprehensive health care services to >3.9 million members. The membership is largely employed, working and middle class, and is highly representative of the racially and socioeconomically diverse northern California population. All study protocols were approved by the KPNC Institutional Review Board.
Sample Selection
Health plan members aged 21 to 80 were eligible if they met criteria for COT for pain (filled Z10 opioid prescriptions and/or received Z120 d supply in the year before sampling, with at Z190 d between the first and last opioid fill in that year; these factors predict high risk for sustained and frequent use of opioids 27 ). The sample was limited to members with continuous KPNC enrollment for >1 year before sampling. Patients who had 2 + cancer diagnoses in automated visit records in the year before sampling or received a cancer diagnosis (except nonmelanoma skin cancer) were excluded, as were patients using buprenorphine and methadone for opioid use disorder. PROC SURVEYSELECT was used to sample equal numbers of eligible patients within 3 daily dosage ranges in the 90 days before the sample selection date (1 to 49 mg, 50 to 99 mg, and 100 + mg morphine equivalent dose [MED] ) to ensure patients with higher dosage levels were included despite their lower prevalence within KPNC.
Interviews were conducted from January, 2008 to October, 2009 by experienced nonclinician survey interviewers. Potentially eligible patients were mailed a letter explaining the study and a $5 gift card preincentive with a toll free number to call to decline participation or contact study investigators for additional information. Interviewers obtained verbal consent and used Computer-Assisted Telephone Interview technology to complete the 45-minute interview. Participants received a $50 gift card in the mail for participating. Overall, 1605 patients at KPNC were approached, out of which 105 were ineligible, and 972 interviews were completed, leading to a response rate of 65%. Response rates were similar across age groups and genders, and increased with higher average daily dose (58% for <50 mg MED, 66% for 50 to 99 mg MED, and 71% for 100 + mg MED). 28 
Measures
Demographic Characteristics
Demographic variables included sex, age (21 to 43; 44 to 64; and 65 + y), employment status (unemployed/ unable to work for health reasons vs. employed), education level, income level, body mass index (BMI), and race/ethnicity (black, Hispanic, non-Hispanic white, other). For analyses limited by sample size in certain strata, we collapsed the "other" race category with the Hispanic group because the 2 groups were most similar in their prescription opioid use and other characteristics.
Smoking Status
Individuals reported whether they were current, former, or never smokers by answering the survey question, "Are you a current smoker, an ex-smoker, or have you never smoked?"
Average Daily Opioid Dose
KPNC maintains automated pharmacy data for all covered services, including those rendered by outside providers who bill the health plan. Data on opioid prescription fills and dosage were extracted from the electronic health record (EHR), which contains 1 record per drug dispensed, generic drug name, strength, directions for use, quantity and date dispensed, days' supply, prescription identification number, and national drug code. Health plan surveys have shown that >90% of patients obtain their prescriptions through KPNC pharmacies. 29 Average daily opioid dose was categorized: <50, 50 to 99, and 100 + mg/d; the daily dose was estimated as the total MED during the 90 days preceding the interview, divided by 90. 28 
Problems and Concerns With Opioids
Problems and concerns attributed to opioids by patients in the past 2 weeks were measured using the Prescribed Opioid Difficulties (PODS), which includes a problems subscale and a concerns subscale. 16, 30, 31 The problems subscale includes 8 items describing interference and side effects associated with opioid use: lost interest in usual activities; trouble concentrating or remembering; felt slowed down or sedated; felt depressed, down, or anxious; side effects interfered with work, family, or social responsibilities; difficulties thinking clearly; felt less alert or sleepy while driving, operating machinery, or doing something else that required being alert, and extent of side effects severity/interference. The concerns subscale includes 7 questions that assess the degree to which the user endorses various types of worries about opioid use: felt preoccupied with opioid use; felt unable to control how much or how often used opioids; needed a higher dose to get the same effect; worried that might be dependent on or addicted to opioids; wanted to stop using or cut down on opioids; opioids have caused problems with family, friends, coworkers in past year; and family or friends thought addicted to or dependent on opioids.
Respondents answered how much they agreed with each statement (strongly disagreed, disagreed, neutral, agreed, or strongly agreed), or specified the frequency of experiencing a given event (never, rarely, sometimes, often, always, or almost every day), on a scale of 0 to 4. The individual scores for each question contributed to each respondent's total score on the subscale. Patient subscale scores were categorized (low, intermediate, and high) based on recommended cutpoints of 0 to 7 (low), 8 to 15 (intermediate), and 16 + (high); a cutpoint of 8 was used for the medium score because this required endorsing at least 2 difficulties, and 16 was used for the high score because this required endorsement of at Z4 difficulties. 16, 30, 31 A dichotomous variable was also created to denote whether patients had experienced a given problem (strongly agree or agree = 1, else = 0; always or almost every day, or often = 1, else = 0).
Pain Intensity
Pain intensity in the past 3 months was measured using the Graded Chronic Pain Scale. 28, 32, 33 Responses to 3 selfreported pain intensity items: pain right now, usual pain, and worst pain (each ranged 0 to 10) were averaged resulting in a 0 to 10 score of overall pain.
Behavioral Health Conditions
Opioid and nonopioid substance use disorder ICD-9 diagnoses in the past 3 years were extracted from the EHR.
Participants were coded as having a self-reported alcohol or drug problem if they responded yes to "Have you ever had an alcohol or drug problem (except tobacco use)?" on the survey. Patients were coded as having used illegal drugs if they reported using the following substances without a medical prescription: cannabis, cocaine, amphetamine stimulants, inhalants, sedatives, hallucinogens, or opiates.
Depression was measured using the 8-item version of the Patient Health Questionnaire, a validated and widely used self-report measure of depression. 34 Scores Z10 were classified as depression. 35 
Statistical Analysis
All statistical analyses were performed in SAS 9.3. Crude frequencies of prescription opioid use, pain perception, and demographic variables were calculated within the 3 strata of smoking status (never, former, and current). Conditional logistic regression and linear regression were used to calculate measures of association between smoking status and opioid characteristics. PROC SURVEYLO-GISTIC and PROC SURVEYREG were used to account for weights in the survey sample, as patients taking higher doses of opiates were oversampled.
For categorical outcomes, ordinal logistic regression was used to estimate associations with smoking status. Ordinal models were retained for precision if the proportional odds assumption was met, indicated by a nonsignificant Score test. Because the Score test is highly sensitive to sample size and often yields a significant P-value despite the presence of an inherently ordered outcome, we plotted the individual logit functions for ordered outcomes that produced a significant P-value under the Score test and assessed whether they were parallel. Parallel logits indicate that the use of an ordinal or ordered model is appropriate, despite a significant Score test. On the basis of the results of these diagnostics, all multinomial outcomes except race were modeled using ordinal logistic regression. In ordinal regression models, the odds ratio can be interpreted as comparing each possible combination of higher categories to the lower categories; for example, it is assumed that the same odds ratio describes the association comparing high versus medium and low categories, as well as high and medium versus low categories. This assumption is supported by the proportional odds assumption and parallel logits.
Analyses were stratified by sex to examine sex-specific associations between smoking and opioid use characteristics. We utilized a change-in-estimate approach to retain covariates that were meaningfully associated with the exposure and outcome, and also included covariates that are well-supported in the literature. [36] [37] [38] Models were adjusted for pain intensity, BMI, race, age, depression, employment status, average daily dose, and substance use disorder, except when the given covariate was the outcome of interest. Covariates removed to maintain parsimony in the model based on the change-in-estimate approach included education level, income level, and illegal drug use.
Finally, we ran bivariate logistic regression models with individual PODS problems items as the outcome to inform the results of multivariate regression models. Statistical significance was evaluated at a = 0.05.
RESULTS
Descriptive Statistics
The sample (N = 972, 37% male, 76% non-Hispanic white) identified as 27% current, 44% former, and 29% never smokers. Other descriptive data for the sample overall and stratified by sex are presented in Table 1 .
Females
Relative to never smokers, current smokers had a lower income, were more likely to be unemployed, and more likely to have an opioid (13% vs. 5%) or nonopioid (23% vs. 9%) substance use disorder. Former smokers had a higher BMI and were less likely to be black (6% vs. 16%) than never smokers. Current (33%) and former smokers (22%) were also more likely than never smokers (11%) to endorse a history of an alcohol or drug use problem, and had slightly higher doses of opioids than never smokers (B90 vs.˜80 mg MED).
Males
Relative to never smokers, current smokers were less likely to have at least some college education, more likely to be Hispanic, more likely to have an opioid (13% vs. 4%) or nonopioid substance use disorder (31% vs. 15%), and more likely to endorse a history of an alcohol or drug use problem (45% vs. 27%). Current smokers were prescribed higher daily doses of opioids on average than never smokers (160 vs. 56 mg MED) (Ps < 0.05). Relative to never smokers, former smokers had a higher BMI, lower income, higher daily dose of opioids (88 vs. 56 mg MED), and were less likely to report medium or high levels (vs. low levels) of problems with opioids.
Multivariate Regression Analyses
Results examining sex-specific associations between smoking status and pain and opioid characteristics are presented in Table 2 . Current smoking was associated with greater opioid doses among males (P = 0.01) but not among females. For both sexes, current smoking was associated with a 2 to 3-fold increase in odds of an opioid use disorder, substance use disorder, or self-reported problem with alcohol or drugs. These associations were nonsignificant among males, likely due to power limitations. However, for both sexes, current and former smokers had significantly lower odds of self-reported problems with opioids relative to never smokers (ORs from 0.34 to 0.53, Ps < 0.05). Smoking status was not associated with pain intensity or reported concerns with opioids.
The odds of reporting specific problems from the PODS problem subscale are reported in Figure 1 , stratified by sex All percentages are weighted by survey sampling weights. *Significantly different from never smokers, P < 0.05. wUnordered outcome modeled using polytomous logistic regression. Ordinal logistic regression used for all ordered outcomes unless otherwise specified. zIncludes those unable to work for health reasons; does not include homemaker. yOn the basis of diagnoses recorded in EHR in past 3 years. 8In past 3 months. BMI indicates body mass index; EHR, electronic health record; MED, morphine equivalent dose; PHQ, Patient Health Questionnaire.
and smoking status. In general, current and former smokers had lower odds of endorsing problems with the sedating properties of opioids (eg, difficulties thinking clearly, felt slowed down, or sedated).
DISCUSSION
Given the current opioid epidemic and increased interest in initiatives to reduce prescription opioid use, 24, 25 identifying factors related to patients' motivation to reduce chronic opioid use is critical. Smoking status appears to be an indicator of risk for problems with opioids, including aberrant opioid use 14 and the development of opioid dependence among chronic pain patients. 15 To our knowledge, this study is the first to examine whether current, former, and never smokers with chronic noncancer pain attribute different problems and concerns to using prescription opioids.
Current smoking was associated with opioid use disorders and general substance use disorders among both males and females. Consistent with prior research, 4 current and former smokers had substantially higher daily doses of prescription opioids relative to never smokers (significant only for males). This is in line with prior findings that despite the analgesic effects of nicotine, chronic cigarette smoking may result in tolerance to nicotine and reduced pain inhibition, possibly mediated by changes in the endogenous opioid system. 1 However, current smoking was only associated with a large increase in opioid dose among males, suggesting that male smokers are still a high-risk group for problematic opioid use who continue to use much higher doses than their nonsmoking counterparts. Current smoking was not associated with greater pain intensity; perhaps smokers were already prescribed higher doses of opioids to manage increased pain sensitivity attributable to chronic smoking. Similar to prior studies of patients with chronic pain, 1 current smokers were more likely than never smokers to have a substance use disorder (including opioids).
Current and former smokers were distinct from never smokers in their perceptions of problems with prescription opioids, indicating different implications by sex given key differences in dosage and behavior patterns. Current and former smokers reported significantly fewer problems with prescription opioids, even after adjusting for covariates. That the association between smoking status and perceived opioid-related problems persisted despite increased odds of an opioid use disorder (among males and females) and elevated opioid doses (among males) is interesting. Prior research on patients' perceived problems with COT indicates that patients who report fewer opioid-related problems are more likely to sustain higher dose opioid use at 1-year follow-up. 30 These findings suggest that current and former smokers are a difficult population to target regarding decreasing or stopping COTs, given their propensity for perceiving fewer drawbacks to prescription opioid therapy despite a greater likelihood of diagnosed abuse and dependence. Male chronic pain patients are at increased risk for opioid misuse relative to females, 23 and males who initiate opioid use for chronic noncancer pain may be more likely than females to escalate to higher doses and die from opioid overdose. 39 Thus, the low levels of reported problems with opioids among male current and former versus never smokers despite elevated opioid doses are concerning.
Whether lower reported problems with opioids among current and former smokers are attributable to underreporting versus actually perceiving fewer problems with opioids is unclear. However, if smokers were underreporting wContinuous variables modeled using linear regression. Logistic regression used unless otherwise specified. zSub-scales from the Prescribed Opioids Difficulties Scale (PODS). BMI indicates body mass index; CI, confidence interval; OR, odds ratio.
symptoms due to social desirability, we would also expect to see lower reported scores on the concerns subscale of the PODS that includes more stigmatized questions about control of opioid medications directly related to opioid abuse (eg, preoccupation with opioid medication and loss of control). We found that current and former smokers were similar to never smokers in their concerns about control of opioid medication use, suggesting that opioids were well tolerated, and lower reported problems with opioids among current and former smokers were not simply due to underreporting. Findings highlight current smokers as at risk for opioid use disorders, but less likely to attribute problems to their use of prescription opioids. Clinicians should address the disconnect between provider-defined problems and smokers' perceptions of opioid-related problems. Smokers' lack of perceived problems with opioids may help explain why some studies find poorer pain treatment outcomes in smokers with chronic pain. 40 For example, Hooten et al 40 found that current smokers (24%) were significantly more likely than former (10%) and never smokers (13%) to drop out of a pain rehabilitation program, although those who completed treatment were as likely as former and never smokers to successfully taper off. Lower endorsement of perceived problems with prescription opioids among current and former smokers appears to be driven by items that are affected by the stimulant properties of nicotine (eg, difficulties thinking clearly, felt less alert or sleepy, felt slowed down, sluggish or sedated). Current and former smokers who attribute fewer of these negative side effects to opioids relative to never smokers may be less motivated to complete pain treatments incorporating opioid tapering.
Alternatively, although smoking prevalence in the United States is declining, the rate of smoking among adults with chronic pain has not declined, 41 and smokers who seek treatment for chronic pain may face increasing smokingrelated stigma, contributing to early dropout.
Most opioid-dependent smokers are motivated to quit smoking 42 and greater pain is not associated with reduced interest in quitting smoking 7, 43 ; yet, quitting success rates are low in this population. 44 Opioid-maintained patients have poor adherence to tobacco cessation medications, 45, 46 and tobacco cessation medications may be less effective among opioid-dependent smokers. 47 Physicians prescribing opioids for patients with chronic pain are well positioned to support attempts to quit smoking, as smoking cessation among patients receiving opioid treatment does not cause poorer opioid outcomes 48 and there is a great opportunity to better serve patients on chronic opioid therapy by embedding tobacco cessation treatment within each patient contact. Given the complex interactions between pain, smoking and opioid medications, careful monitoring of opioid dose after smoking abstinence also is important, as painful symptoms and nicotine withdrawal may complicate short-term efforts to treat pain. 4 Initial data support the efficacy of a cognitive behavioral smoking abstinence intervention for adults with chronic pain that was integrated into the treatment protocols of an outpatient multidisciplinary pain rehabilitation program. 49 Additional research is needed to further develop and test efficacious, patient-centered interventions for tobacco smoking that are integrated into clinical treatment for chronic pain.
KPNC provides a well-identified population supported by rich, longitudinal data sources. KPNC's integrated health system with a robust EHR allowed for data validation of substance use disorder history and granular information regarding opioid use and dosage. However, many outcomes of interest were self-reported and the survey did not include details on heaviness of smoking (for current smokers), duration of abstinence from cigarettes (for former smokers), or duration of time on opioids. In addition, opioid dosage information was based on data from the EHR. Given that individuals who misuse prescription opioids may escalate their use without a doctor's permission (eg, by obtaining additional prescriptions or purchasing opioids illegally), EHR dosage information may underestimate patients' actual use. Further, current and former smokers may be more likely to receive an opioid use disorder diagnosis with similar or fewer abuse and dependence symptoms than never smokers (eg, due to provider bias, being flagged as risk takers). Finally, the study was limited by a relatively small sample size of males, limiting power to assess associations in this group.
This study contributes to an understanding of perceived problems and concerns with COT among current, former, and never smokers with chronic noncancer pain. Current and former smokers attributed fewer problems to their use of prescription opioid medications relative to never smokers despite increased odds of meeting the criteria for an opioid use disorder in the past three years. Smokers with chronic pain present complex cases for healthcare providers, who should provide a collaborative framework for discussing the bidirectional relation between smoking and pain. Clinicians' conversations with smokers on COT should include a patient-centered assessment of opioidrelated problems and concerns, education about coping responses other than smoking cigarettes to manage pain, advice to quit, and assistance with tobacco cessation. In addition, large discrepancies in opioid dose between male and female current smokers, despite increased risk of opioid use disorders in both groups, suggests that male and female smokers may require varied approaches to pain management to prevent future problematic opioid use. Further, providers should distinguish former and never smokers during treatment for chronic pain, as both current and former smokers may benefit disproportionately from psychoeducation about the relation between prescription opioids and problems with mood and cognition, and the provision of tools to help them recognize and monitor psychosocial difficulties attributed to COT. Given the significant negative health consequences of smoking and opioid addiction and the dearth of research on smokers' experiences with prescription opioids, additional studies are needed. Of specific interest is whether and how smoking interacts with opioid medications to produce fewer perceived negative side effects among current and former smokers, despite their elevated risk for opioid use disorders.
